IndonesiaTuberculosis profile
Population  2015 258 million
Estimates of TB burden*, 2015 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 100 (67–150) 40 (26–57)
Mortality (HIV+TB only) 26 (20–34) 10 (7.6–13)
Incidence  (includes HIV+TB) 1 020 (658–1 450) 395 (255–564)
Incidence (HIV+TB only) 78 (48–116) 30 (18–45)
Incidence (MDR/RR-TB)** 32 (19–45) 12 (7.4–17)
Estimated TB incidence by age and sex (thousands)*, 2015
  0-14 years > 14 years Total
Females 36 (16–57) 384 (194–573) 420 (210–630)
Males 39 (23–54) 559 (391–726) 597 (415–780)
Total 75 (49–100) 942 (730–1 150) 1 020 (658–1 450)
TB case notifications, 2015  
Total cases notified 330 729
Total new and relapse 328 895
          - % tested with rapid diagnostics at time of diagnosis  
          - % with known HIV status 11%
          - % pulmonary 93%
          - % bacteriologically confirmed among pulmonary 64%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2015 32% (23–50)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2015 0.13 (0.08–0.21)
TB/HIV care in new and relapse TB patients, 2015 Number (%)
Patients with known HIV-status who are HIV-positive 3 523 10%
          - on antiretroviral therapy 757 21%
Drug-resistant TB care, 2015 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  10 000
(8 000–12 000)
Estimated % of TB cases with MDR/RR-TB 2.8% (2.2–3.5) 16% (10–20)  
% notified tested for rifampicin resistance <1% 80% 9 764
MDR/RR-TB cases tested for resistance to second-line drugs   895
Laboratory-confirmed cases MDR/RR-TB: 2 135, XDR-TB: 28
Patients started on treatment **** MDR/RR-TB: 1 519, XDR-TB: 22
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2014 84% 322 806
Previously treated cases, excluding relapse, registered in 2014 63% 1 733
HIV-positive TB cases, all types, registered in 2014 56% 2 548
MDR/RR-TB cases started on second-line treatment in 2013 51% 809
XDR-TB cases started on second-line treatment in 2013 40% 10
TB preventive treatment, 2015  
% of HIV-positive people (newly enrolled in care) on preventive treatment 2%
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
 
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2015
age_sex_graph
____
FemalesMales

Treatment success rate (%)
tx success graph
   
New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2017-01-24 Data: www.who.int/tb/data